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Edited by Takashi GojoboriAbstract Secreted proteins are indispensable for the develop-
ment and diﬀerentiation of multicellular organisms. Cloning and
characterization of novel or hypothetical genes encoding these
proteins are therefore inviting great incentives. Using bioinfor-
matics tools and experimental approaches, we isolated and
characterized a human secreted glycoprotein, hOLF44, which
contains a highly conserved olfactomedin-like (OLF) domain in
the C-terminal. However, phylogenetic analysis revealed that
hOLF44 is not clustered into any of the OLF subfamilies
containing characterized members, and obviously falls into a
newly identiﬁed uncharacterized OLF subfamily. Western blot
analysis showed that hOLF44 protein is robustly secreted from
the transfected COS-7 cells. Expression levels of hOLF44
mRNA are abundant in placenta, moderate in liver and heart,
whereas fairly weak in other tissues examined. Immunohisto-
chemical study on human term placenta demonstrated that
hOLF44 is mainly localized extracellularly surrounding the
syncytiotrophoblastic cells and very rarely expressed in the
maternal decidua layer. These results suggest that hOLF44 may
have matrix-related function involved in human placental and
embryonic development, or play a similar role in other physio-
logical processes. The further functional characterization of
hOLF44 may provide insights into a better understanding of the
newly identiﬁed OLF subfamily.
 2004 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
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Secreted proteins play an essential role in the development,
diﬀerentiation and maintenance of multicellular organisms.* Corresponding author. Fax: +86-21-63852655.
E-mail address: wjma@sibs.ac.cn (W.-J. Ma).
q Nucleotide sequence and protein sequence of hOLF44 have been
deposited to GenBank database with Accession Nos. AY464015 and
AAR88262, respectively.
Abbreviations: OLF, olfactomedin-like; SST, signal sequence trap;
EST, expressed sequence tag; ECM, extracellular matrix
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secreted proteins may not only provide insights into the un-
derstanding of the crucial biological processes that these
molecules govern, but also oﬀer new opportunities for the
development of drug therapies. In particular, secreted pro-
teins possess properties that lend themselves to be utilized as
therapeutic agents or targets [1]. Thus, from a pharmaceutical
perspective, secreted proteins indicate a great potential in the
treatment of major diseases, and thus systematic screening
and cloning of genes encoding these proteins are of particular
interest. Several methods were therefore developed to screen
secreted proteins. Tashiro et al. [2] invented one eﬀective
method, signal sequence trap (SST), by exploiting the ability
of the signal peptide to lead proteins outside of the plasma
membrane. However, some drawbacks, including consider-
able time-consuming, high cost and high redundancy of
known genes, are still wrapped with the SST method. With
the availability of the avalanche of DNA and protein se-
quence information, a computer based prediction method,
SignalP [3], has emerged, and this method is, in principle,
more suitable for us to trap novel or hypothetical secreted
proteins compared with the SST method.
In order to isolate novel or hypothetical genes encoding se-
creted proteins involved in intercellular signaling, we utilized
SignalP [3] to predict the putative secreted proteins from in-
house EST (expressed sequence tag) database generated by our
transcriptome projects [4,5]. Many in silico protein sequences
possessing a putative signal peptide were obtained through
bioinformatics analysis. Interestingly, ﬁve of themwere found to
contain a large olfactomedin-like (OLF) domain, and their
amino acid sequences are 46–99% similar to that of an OLF
protein playing a crucial role in neural development [6,7]. Ad-
ditionally, some of the characterized OLF proteins are also in-
volved in various developmental processes. This ﬁnding
motivated us to categorize the ﬁve OLF sequences we trapped,
but simple highest-hit method gave incomprehensive results
because of the complexity of the OLF family. Our further phy-
logenetic analysis on more OLF proteins clustered four of the
ﬁve OLF sequences into a few OLF subfamilies containing
characterizedmembers, whereas the other one, named hOLF44,
fell into a newly identiﬁed OLF subfamily, in which all the
members have not been characterized yet. The distinction ofblished by Elsevier B.V. All rights reserved.
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we report the identiﬁcation, isolation and preliminary charac-
terization of a secreted glycoprotein, hOLF44, which belongs to
an uncharacterized OLF subfamily newly identiﬁed by phylo-
genetic analysis.2. Materials and methods
2.1. Trapping for human novel or hypothetical secreted proteins
SignalP, a computer on-line program designed for searching signal
sequences and their cleavage sites [3], was employed to predict the
putative secreted proteins. We deﬁned a positive SignalP hit as the
simultaneous presence of three criteria: (a) signal peptide predicted by
SignalP-NN; (b) signal peptide predicted by SignalP-HMM; and
(c) signal peptide cleavage site located within 10–50 amino acids from
the N-terminal.
2.2. Sequence alignment and phylogenetic analysis
Almost all currently available OLF protein sequences from the
major species extensively sequenced were retrieved from Smart data-
base [8]. After the redundancy (alternately spliced transcripts of the
same gene) was eliminated, the full-length OLF protein sequences were
aligned using ClustalW program [9] with the default settings. Phylo-
genetic trees were constructed from the resulting multiple sequence
alignments using minimum-evolution [10] and neighbor-joining [11]
methods, as implemented in the MEGA2 program [12]. The Poisson
correction model was used for distance matrix calculations and sites
containing missing data or alignment gaps were removed in a com-
plete-deletion fashion. Reliability of the phylogenetic trees was ex-
amined by bootstrap [13] test with 1000 replications using the same
computer package. The two methods gave virtually identical results for
our datasets. Only the minimum-evolution tree is shown in this paper,
as the minimum-evolution method is known to be more eﬃcient than
most other distance methods for phylogenetic inference [10]. Since the
protein repertoire between mouse and rat is almost identical, only the
mouse OLF proteins were presented in the phylogenetic tree in this
paper.
2.3. Cloning of hOLF44 gene
The in silico hOLF44 gene was obtained from in-house EST data-
base and relevant public EST database using in silico cloning method.
The coding region of hOLF44 was ampliﬁed from total RNA of hu-
man adult liver by RT-PCR using the following two primers based on
the in silico hOLF44 gene: 50-GGAATTCACTCTCCAGGCTGC-
CATG-30 and 50-GGGGTACCAACCTCCTCCTCTTTCTTCCTC-
30. The PCR product, designated as hOLF44-ORF, was then cloned
into pcDNA3.1-A (Invitrogen) with a c-Myc tag in the C-terminal and
veriﬁed by DNA sequencing. The resulting construct was designated as
pcDNA3.1-hOLF44-Myc.
2.4. In vitro transcription and translation of hOLF44
The construct pcDNA3.1-hOLF44-Myc was transcribed and trans-
lated in the presence of [35S]methionine using TNT coupled tran-
scription/translation system (Promega). The synthesized proteins were
separated by 12% SDS–polyacrylamide gel electrophoresis (PAGE)
and signal was visualized by autoradiography.
2.5. Northern blot analysis
Northern blot analysis was performed on Human 12-lane Multiple
Tissue Northern Blot (Clontech). hOLF44-ORF was used as a tem-
plate to generate the probe which was labeled with [a-32P]dCTP.
Prehybridization, hybridization and washing were performed accord-
ing to Clontech’s protocol. Hybridization signals were visualized by
autoradiography. The same blot was stripped and re-hybridized with a
2 kb human b-actin probe to verify that all lanes contain comparable
amounts of mRNA.
2.6. Cell transfection and Western blot analysis
Cell transfection experiment was performed with Lipofectamine
according to the manufacturer’s protocol (Invitrogen). Both culture
medium and cell lysate of the transfected COS-7 cells were enriched
using TALON metal aﬃnity resins (Clontech). The enriched sampleswere separated on 12% SDS–PAGE and transferred onto PVDF
membrane (Amersham Biosciences). The membrane was blocked and
then incubated with c-Myc monoclonal antibody (Clontech), followed
by incubation with goat horseradish peroxidase-conjugated anti-mouse
antibody (Invitrogen). The immune complexes were visualized by
chemiluminescence kit (ECL, Amersham Biosciences). For degly-
cosylation experiment, the enriched hOLF44 protein sample from
culture medium was subject to deglycosylation with PNGase F ac-
cording to the manufacturer’s protocol (New England BioLabs).
2.7. Immunoﬂuorescence microscopy
COS-7 cells growing on glass coverslips were transfected with the
construct pcDNA3.1-hOLF44-Myc. After incubation at 37 C for 60
h, the transfected cells were ﬁxed in 2% paraformaldehyde (PFA) at 4
C for 30 min. Then, the ﬁxed cells were blocked with 5% BSA and
incubated with c-Myc monoclonal antibody (Clontech) at 4 C over-
night, followed by goat ﬂuorescein isothiocyanate (FITC)-conjugated
anti-mouse IgG (Invitrogen). Coverslips were mounted and then ex-
amined by immunoﬂuorescence light microscopy.
2.8. Antibody generation and immunohistochemistry
The cDNA fragment encoding the N-terminal (residues 22–271) of
hOLF44 was subcloned into pGEX-5x-1 vector resulting in glutathi-
one S-transferase (GST)-hOLF44 construct. GST-hOLF44 fusion
proteins were produced and puriﬁed using Glutathione Sepharose 4B
(Amersham Biosciences) according to the manufacturer’s protocol.
Rabbits were immunized with standard procedures using 2 mg of GST-
hOLF44 fusion proteins as antigen for injection. The antisera were
puriﬁed using Protein G Sepharose 4 Fast Flow (Amersham Bio-
sciences) and then the anti-GST antibody was removed according to
the manufacturer’s instructions. The resulting puriﬁed polyclonal an-
tibody was designated as anti-hOLF44. Rabbit polyclonal pre-immune
serum was obtained prior to immunization and parallelly processed.
The resulting puriﬁed pre-immune antibody was used as a negative
control.
Human term placenta was midsagittally excised and routinely ﬁxed
in 4% PFA. After dehydration with ethanol and xylene, the ﬁxed
samples were embedded in paraﬃn wax using standard procedures.
Paraﬃn blocks containing samples were then sagittally sectioned with
a microtome at 5 lm and mounted on subbed slides. After dewaxing
and rehydration, sections were incubated in freshly made 3% H2O2/
methanol to remove any endogenous peroxidase activity. After diges-
tion with 4% pepsin, the sections were blocked and then incubated with
anti-hOLF44 polyclonal antibody at 4 C overnight, followed by in-
cubation with goat horseradish peroxidase-conjugated anti-rabbit IgG
(Dako Japan Ltd.). The signals were detected with Diaminobenzidine
(DAB) substrate kit (Vector Laboratories, Inc.). Sections were then
counterstained with methyl green to identify nuclei.3. Results
3.1. hOLF44 falls into an uncharacterized OLF subfamily newly
identiﬁed by phylogenetic analysis
In order to categorize the ﬁve OLF sequences we trapped
(clone number corresponding to in-house ESTs: AV702260,
AV722944, AV722100, AV723866 and AV713200, respec-
tively), we ﬁrst used the common highest-hit homology method
to analyze them, but it gave incomprehensive results because of
the complexity of the OLF family. Thus, we performed phy-
logenetic analysis on available full-length OLF proteins from
the major species extensively sequenced. The resulting phylo-
genetic tree showed that four of the ﬁve OLF sequences fell
into a few OLF subfamilies containing well-characterized
members. For example, AV702260 and AV722944 were clus-
tered into the latrophilin subfamily; AV722100 and AV723866
fell into the noelin subfamily (Fig. 1). However, AV713200 was
not clustered into any of the OLF subfamilies containing
characterized members, and fell into a newly identiﬁed
OLF subfamily, in which all the members have not been
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a distinct OLF member and characterization of it becomes
more attractive, and we named it hOLF44 after its predicted
molecular weight of 44 kDa. Nucleotide sequence and pro-
tein sequence of hOLF44 have been deposited to GenBank
database with Accession Nos. AY464015 and AAR88262,
respectively.
3.2. Isolation, cloning and structural analysis of hOLF44
The coding region of hOLF44 was cloned by RT-PCR
method and the sequencing result conformed to the in silico
hOLF44 sequence and relevant sequences deposited in public
database. The full-length cDNA sequence of hOLF44 consists
of approximately 1.8 kb and the longest open reading frameFig. 1. hOLF44 belongs to a newly identiﬁed uncharacterized OLF
subfamily. The phylogenetic tree was constructed from the multiple
alignments of the full-length OLF protein sequences using minimum-
evolution [10] method. Numbers above the branches represent the
bootstrap values [13] based on 1000 replicates. The proteins are named
using an abbreviated species name followed by a gene label. Accession
numbers are listed at the left of their corresponding proteins. hOLF44
is boxed. Previously reported human OLF sequences, hOlfA-hOlfD
[14], are depicted at the right of their corresponding protein. The ﬁve
OLF proteins we trapped are labeled with the corresponding clone
numbers of in-house ESTs (AV713200, AV702260, AV722944,
AV722100 and AV723866, respectively). Hs, Homo sapiens; Mus, Mus
musculus; Gal, Gallus gallus; Xen, Xenopus laevis; Ran, Rana cates-
beiana, Dm, Drosophila melanogaster; Cel, Caenorhabditis elegans;
Spu, Strongylocentrotus purpuratus. For more details on tree genera-
tion, see Section 2.encodes a protein with a predicted molecular weight of
44 kDa. The start codon is surrounded by a homologous
Kozak consensus sequence (GCCATGG) [15]. hOLF44 gene
locus was mapped within chromosome 1p13.1 by searching the
human genome database in NCBI, and the genomic structure
is composed of three exons and two introns that cover a
minimum of 2.9 kb. All these exon-intron splice junctions
conform to the GT/AG rule [16].
Bioinformatic analysis of the predicted protein of hOLF44
revealed that it has a signal peptide in the N-terminal (residues
1–21), two potential N-glycosylation sites (residues 177 and
248) in the middle region, and a large OLF domain in the
C-terminal (residues 135–401). To better characterize the
structural property of hOLF44, we performed sequence and
secondary structure comparisons between hOLF44 and other
well-characterized OLF members, including olfactomedin,
myocilin, noelin, tiarin, amassin and pDP4. Secondary struc-
ture predictions were performed using sequence alignments as
input for Jpred [17]. The result showed that the C-terminal
(OLF domain) of hOLF44 mainly contains b-strands motif
(though two a-helixes are predicated), whereas the N-terminal
of it consists of a-helixes (Fig. 2A). Although the sequence
similarity between hOLF44 and the other well-characterized
OLF members is not very high (approximately 45%), they
obviously share similar structural motifs and the key residues
that stabilize the OLF domain structure are suﬃciently con-
served during evolution (Fig. 2A). Furthermore, their domain
architecture was found to be strikingly similar in the presence,
size and orders (Fig. 2B).
3.3. hOLF44 is a secreted glycoprotein
To determine whether hOLF44 is secreted, the construct
pcDNA3.1-hOLF44-Myc was transiently transfected into
COS-7 cells, both the culture medium and the cell lysate were
analyzed by Western blot using c-Myc antibody. For negative
and positive controls, vector pcDNA3.1-A and the construct
pcDNA3.1-hGH-Myc (hGH, human growth hormone) were
parallelly processed. A speciﬁc protein band of approximately
60 kDa was detected in both culture medium and cell lysate
(Fig. 3A, lanes 3 and 6). The size of the detected band was
showed to be much larger than that of the predicted protein
molecular weight of hOLF44. Since hOLF44 contains two
potential N-glycosylation sites (residues 177 and 248), we next
tested whether this phenomenon is due to glycosylation by
treatment of the enriched hOLF44 protein sample with a de-
glycosylating enzyme PNGase F. After treatment with PNG-
ase F, the size of the detected band was approximately 49 kDa,
which was the predicted size of the Myc-tagged hOLF44
protein (Fig. 3B, lane 2). It is equivalent to that of in vitro
translated protein from pcDNA3.1-hOLF44-Myc (Fig. 3B,
lane 3). Taken together, these data strongly demonstrate that
hOLF44 is a secreted glycoprotein. Additionally, the experi-
mental results provided proof for the aforementioned bioin-
formatics predictions.
3.4. hOLF44 mRNA was abundantly expressed in placenta
To ﬁnd clues to the functional involvement in vivo, the
mRNA expression pattern of hOLF44 was investigated by
Northern blot analysis, which was carried out on Human 12-
lane Multiple Tissue Northern Blot from Clontech. The result
showed that to some extent hOLF44 mRNA was diﬀerentially
expressed in multiple tissues (Fig. 4). Approximately 1.8 kb
Fig. 2. Sequence and domain architecture comparisons between hOLF44 and other well-characterized OLF members. (A) Full-length sequence
comparison between hOLF44 and other well-characterized OLF members. Identical amino acid residues are dark-shaded and similar residues are
shaded at various degrees. Ellipses indicate the conserved glycosylation sites (residues 177 and 248). The percentage indicates the sequence similarities
relative to hOLF44. The predicted secondary structural motifs are depicted with arrows for b-strands and cylinders for a-helixes. (B) Domain ar-
chitecture comparison among these seven full-length OLF members. From N-terminal to C-terminal, there is a signal peptide sequence, a long coiled-
coil motif and the OLF domain.
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Fig. 3. Secretion and deglycosylation analyses of hOLF44. (A) Myc-tagged hOLF44 protein is robustly secreted from the transfected COS-7 cells
(lane 3). pcDNA3.1-A and pcDNA3.1-hGH-Myc are the negative and positive controls, respectively. Lanes 1, 2 and 3 are the enriched samples from
culture medium; lanes 4, 5 and 6 are the enriched samples from the corresponding cell lysate. An arrow at the right indicates the position of the
expressed Myc-tagged hOLF44 protein. Proteins were detected with c-Myc antibody. (B) Deglycosylation of the enriched hOLF44 protein sample
from culture medium (CM) of transfected COS-7 cells. After treatment with PNGase F (lane 2), the size of detected Myc-tagged hOLF44 protein
band is reduced and is very close to that of the in vitro translated protein (IVT) from pcDNA3.1-hOLF44-Myc (lane 3). Proteins were detected with
c-Myc antibody. CM, culture medium; IVT, in vitro translated protein.
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Moderate expression was observed in liver and heart, and
fairly weak signals were also detected in skeletal muscle, small
intestine, lung and kidney. Very weak signals were observed in
colon, thymus, spleen and brain, whereas in peripheral blood
leukocyte, no signal could be detected at this level of sensi-
tivity. Additionally, fairly weak signals of smaller bands were
detected in heart, skeletal muscle and placenta, and they may
represent alternative splicing variants.Fig. 4. hOLF44mRNA is diﬀerentially expressed in various tissues and
is particularly abundant in placenta. Human 12-Lane Multiple Tissue
Northern Blot from Clontech was hybridized with a-32P-labeled probe
for hOLF44 and the 2 kb human b-actin cDNA as control for total
mRNA quantiﬁcation. Size standards and the order of tissues source
are marked at the left and top of the blot, respectively.3.5. Cellular and subcellular localization of hOLF44 protein
To clarify the localization of hOLF44, we utilized two
methods to resolve this issue, including immunoﬂuorescence
for Myc-tagged hOLF44 protein and immunohistochemical
staining for the endogenous hOLF44 protein. COS-7 cells were
transfected with the construct pcDNA3.1-hOLF44-Myc, and
the immunoﬂuorescence assay with c-Myc antibody showed
that Myc-tagged hOLF44 protein was preferentially detected
in the perinuclear regions (Fig. 5A), most likely in the endo-
plasmic reticulum (ER), which is the common feature of se-
creted proteins. Furthermore, we also investigated the
localization of endogenous hOLF44 protein in human placenta
where its transcripts exhibit the strongest expression according
to our Northern blot analysis. Immunohistochemical staining
with rabbit anti-hOLF44 primary antibody on human term
placenta sections (sagittally sectioned at 5 lm) showed that
strong signals were detected extracellularly surrounding the
syncytiotrophoblastic cells (ST) on the fetal side (Fig. 5C),
whereas very rare signal was detected in the maternal decidua
(MD) layer. With puriﬁed pre-immune antibody for the neg-
ative control, no such signal was detected (Fig. 5B). Addi-
tionally, our immunohistochemical studies on cryosections of
human adult normal and cancerous livers also revealed that
hOLF44 was localized extracellularly surrounding hepatocytes
(data not shown).4. Discussion
In this study, we isolated and preliminarily characterized
human hOLF44, a secreted glycoprotein diﬀering from other
previously reported human OLF proteins. The members in the
OLF family all contain a highly conserved OLF domain at the
C-terminal, whereas the N-terminal of them is more variable
[18]. Another common feature of the most characterized OLF
members is that their mRNA expression patterns are highly
selective. For example, myocilin/TIGR, a secreted protein that
Fig. 5. Immunoﬂuorescence and immunohistochemical detection of hOLF44 protein. (A) Subcellular localization of Myc-tagged hOLF44 protein.
COS-7 cells were transfected with pcDNA3.1-hOLF44-Myc. Immunostaining was carried out using c-Myc antibody as the primary antibody and
FITC-conjugated goat anti-mouse IgG as the secondary antibody. Arrow indicates the Myc-tagged hOLF44 protein stained with green immuno-
ﬂuorescence in the perinuclear regions. (B and C) Immunohistochemical detection of endogenous hOLF44 protein in human term placenta sections,
sagittal view. (B) Puriﬁed pre-immune antibody incubation is presented as negative control. (C) Section was incubated with rabbit anti-hOLF44
polyclonal antibody as the primary antibody and arrows indicate the representative positive staining. All sections were counterstained with methyl
green. Magniﬁcations: A, 400; B and C, 200.
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[19], is selectively expressed in heart, skeletal muscle, brain and
retina [14,20]. The previously reported human OLF sequences,
hOlfA–hOlfD/hGC-1/GW112 and optimedin, all show distinct
expression patterns with hOlfD/hGC-1/GW112 in colon, small
intestine and prostate [14,21,22] and hOlfB in pancreas and
prostate [14]. Since hOlfA, hOlfC and optimedin all fall into a
relevant subfamily (Fig. 1), they share similar expression pat-
terns in brain [14,20]. However, hOLF44 is diﬀerentially ex-
pressed in multiple tissues with particularly abundant
expression in placenta and moderate expression in liver and
heart. Additional weak signals of smaller bands were detected
in heart, skeletal muscle and placenta. This may imply that
there exists alternative splicing variants in diﬀerent tissues.
However, this phenomenon needs further experimental con-
ﬁrmation. So in this case, hOLF44 diﬀers greatly from any of
the aforementioned human OLF members belonging to other
OLF subfamilies.
Although the biological functions of most OLF members
were not well elucidated, some characterized members were
found to be involved in the formation of the extracellular
matrix (ECM). Olfactomedin is an ECM protein surrounding
the bullfrog olfactory neurons [23,24]. Two recent reports on
invertebrate OLF members found that amassin functions as a
cell adhesion protein in sea urchin coelomocytes [25] and
UNC-122 may act as a structural component of the neuro-
muscular junctions in Caenorhabditis elegans [26]. Accord-
ingly, hOLF44 is localized extracellularly surrounding the
syncytiotrophoblastic cells, which are the major structural
components of human placental villous chorion and play a
crucial role in the development and maintenance of placenta
[27,28]. Additional immunohistochemical staining on human
liver sections shows that hOLF44 is localized extracellularly
surrounding hepatocytes. These observations imply that
hOLF44 may form ECM structure by interacting with other
components. Additionally, hOLF44 is heavily glycosylated
and this glycosylation may play a role in the folding, stability,
traﬃcking and/or function of this protein.
Furthermore, several OLF members, including noelin [6,7],
tiarin [29] and pDP4 [30], are all implicated in developmental
processes. Since hOLF44 contains a highly conserved OLF
domain and shares similar structural properties with them
(Fig. 2), it may also play a similar role in particular develop-
mental processes. Based on its particular mRNA expressionpattern and ability to form ECM structure in human placenta
and liver, we suggest that hOLF44 may act as a matrix-related
component involved in placental and embryonic development
or play a similar role in liver and other tissues.
In conclusion, hOLF44 is a secreted glycoprotein and falls
into a newly identiﬁed uncharacterized OLF subfamily. Our
ﬁndings suggest that hOLF44 may serve as a matrix-related
eﬀector in human placental and embryonic development or
play a similar role in other physiological processes. Our ex-
perimental results also demonstrate that bioinformatics tools,
to some extent, are reliable for guiding functional studies of
uncharacterized genes. Further studies in mouse, where genetic
ablation is possible would promise to uncover important clues
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